COVID-19 and the liver: an adverse outcome pathway perspective
- PMID: 33771662
- PMCID: PMC7986318
- DOI: 10.1016/j.tox.2021.152765
COVID-19 and the liver: an adverse outcome pathway perspective
Abstract
Liver damage is observed in up to half of hospitalized COVID-19 patients and can result either from actions of SARS-CoV-2 as such or from pharmacological treatment. The present paper introduces an adverse outcome pathway construct that mechanistically describes the pathways induced by SARS-CoV-2 leading to liver injury. This can be caused by direct binding of the virus and local actions in cholangiocytes, but may also indirectly result from the general state of hypoxia and systemic inflammation in COVID-19 patients. Further research is urgently needed to fill remaining knowledge gaps. This will be anticipated to create a solid basis for future and more targeted development of vaccines and, in particular, therapies.
Keywords: AOP; COVID-19; Liver; Mechanism; SARS-CoV-2.
Copyright © 2021 Elsevier B.V. All rights reserved.
Conflict of interest statement
The author declares that he has no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Figures
Similar articles
-
Molecular and cellular mechanisms of liver dysfunction in COVID-19.Discov Med. 2020 Sep-Oct;30(160):107-112. Discov Med. 2020. PMID: 33382966 Review.
-
Angiotensin-Converting-Enzyme 2 and Renin-Angiotensin System Inhibitors in COVID-19: An Update.High Blood Press Cardiovasc Prev. 2021 Mar;28(2):129-139. doi: 10.1007/s40292-021-00439-9. Epub 2021 Feb 26. High Blood Press Cardiovasc Prev. 2021. PMID: 33635533 Free PMC article. Review.
-
Potential therapeutic approaches for the early entry of SARS-CoV-2 by interrupting the interaction between the spike protein on SARS-CoV-2 and angiotensin-converting enzyme 2 (ACE2).Biochem Pharmacol. 2021 Oct;192:114724. doi: 10.1016/j.bcp.2021.114724. Epub 2021 Aug 8. Biochem Pharmacol. 2021. PMID: 34371003 Free PMC article. Review.
-
Designing therapeutic strategies to combat severe acute respiratory syndrome coronavirus-2 disease: COVID-19.Drug Dev Res. 2021 Feb;82(1):12-26. doi: 10.1002/ddr.21720. Epub 2020 Jul 30. Drug Dev Res. 2021. PMID: 33216381 Review.
-
The Repurposed ACE2 Inhibitors: SARS-CoV-2 Entry Blockers of Covid-19.Top Curr Chem (Cham). 2021 Oct 8;379(6):40. doi: 10.1007/s41061-021-00353-7. Top Curr Chem (Cham). 2021. PMID: 34623536 Free PMC article. Review.
Cited by
-
scCross: a deep generative model for unifying single-cell multi-omics with seamless integration, cross-modal generation, and in silico exploration.Genome Biol. 2024 Jul 29;25(1):198. doi: 10.1186/s13059-024-03338-z. Genome Biol. 2024. PMID: 39075536 Free PMC article.
-
Building an Adverse Outcome Pathway network for COVID-19.Front Syst Biol. 2024 Jun 6;4:1384481. doi: 10.3389/fsysb.2024.1384481. Front Syst Biol. 2024. PMID: 40206642 Free PMC article.
-
Factors Modulating COVID-19: A Mechanistic Understanding Based on the Adverse Outcome Pathway Framework.J Clin Med. 2022 Jul 31;11(15):4464. doi: 10.3390/jcm11154464. J Clin Med. 2022. PMID: 35956081 Free PMC article. Review.
-
CIAO: a living experiment in interdisciplinary large-scale collaboration facilitated by the Adverse Outcome Pathway framework.Front Public Health. 2023 Aug 10;11:1212544. doi: 10.3389/fpubh.2023.1212544. eCollection 2023. Front Public Health. 2023. PMID: 37637826 Free PMC article.
-
Direct, indirect, post-infection damages induced by coronavirus in the human body: an overview.Virusdisease. 2022 Dec;33(4):429-444. doi: 10.1007/s13337-022-00793-9. Epub 2022 Oct 25. Virusdisease. 2022. PMID: 36311173 Free PMC article. Review.
References
-
- Ankley G.T., Bennett R.S., Erickson R.J., Hoff D.J., Hornung M.W., Johnson R.D., Mount D.R., Nichols J.W., Russom C.L., Schmieder P.K., Serrrano J.A., Tietge J.E., Villeneuve D.L. Adverse outcome pathways: a conceptual framework to support ecotoxicology research and risk assessment. Environ. Toxicol. Chem. 2010;29:730–741. - PubMed
-
- Brosnahan S.B., Smilowitz R.S., Amoroso N.E., Barfield M., Berger J.S., Goldenber R., Ishida K., Talmor N., Torres J., Yaghi S., Yuriditsky E., Maldonado T.S. Thrombosis at hospital presentation in patients with and without coronavirus disease 2019. J. Vasc. Surg. Venous Lymphat. Disord. 2021 in press. - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous